<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154598">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756391</url>
  </required_header>
  <id_info>
    <org_study_id>R01 AI 0739654</org_study_id>
    <nct_id>NCT01756391</nct_id>
  </id_info>
  <brief_title>Allergens in Inner-City Schools and Childhood Asthma</brief_title>
  <official_title>Allergens in Inner-City Schools and Childhood Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Boston</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a disease that affects more than 12% of Americans under the age of 18 for over 14
      million missed school days per year, and is the number one cause of school absences in
      America. Elementary school children spend 6 to 10 hours a day in school, and most of that
      time is spent in one classroom. The goals of this project are to provide an understanding of
      exposure risk factors specific to the classroom. This is critical, because the classroom
      environment could potentially be considered as an effective target for prevention of
      inner-city asthma morbidity by reducing exposures to many symptomatic children through an
      intervention in the school classrooms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>maximum days of symptoms/ 2 weeks</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum days of asthma symptoms will be assessed by questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>days of slowed activity due to asthma</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of exercise-induced symptoms</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of cough without an upper respiratory infection</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nights of wakening due to asthma symptoms</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>emergency department visits</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unscheduled physician/health care visits</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prednisone bursts</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 percent predicted</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change in FEV1 after short-acting beta agonist</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exhaled nitric oxide levels</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Asthma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        elementary school students with asthma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grades K-8 the school year following spring recruitment  (Ages 5-15)

          -  Attend one of the schools in the fall where permission obtained for classroom
             sampling.

          -  Able to provide assent and parent/guardian able to provide informed consent
             Physician-Diagnosed asthma AND Wheezing in the previous 12 months

        Exclusion Criteria:

          -  Significant pulmonary diseases other than asthma that might influence test results or
             pose risks (e.g., cystic fibrosis, sarcoidosis, bronchiectasis)

          -  Cardiovascular disease that requires daily medication

          -  Taking a beta blocker

          -  Active smoker

          -  Unable to follow through with study visit or complete study procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wanda Phipatanakul, MD, MS</last_name>
    <phone>857-218-5336</phone>
    <email>wanda.phipatanakul@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Bailey</last_name>
    <phone>617-525-0876</phone>
    <email>ann.bailey@channing.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Phipatanakul, MD, MS</last_name>
      <phone>857-218-5536</phone>
      <email>wanda.phipatanakul@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Wanda Phipatanakul, MD,MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Phipatanakul W, Matsui E, Portnoy J, Williams PB, Barnes C, Kennedy K, Bernstein D, Blessing-Moore J, Cox L, Khan D, Lang D, Nicklas R, Oppenheimer J, Randolph C, Schuller D, Spector S, Tilles SA, Wallace D, Sublett J, Bernstein J, Grimes C, Miller JD, Seltzer J. Environmental assessment and exposure reduction of rodents: a practice parameter. Ann Allergy Asthma Immunol. 2012 Dec;109(6):375-87. doi: 10.1016/j.anai.2012.09.019.</citation>
    <PMID>23176873</PMID>
  </reference>
  <reference>
    <citation>Bartnikas LM, Sheehan WJ, Hoffman EB, Permaul P, Dioun AF, Friedlander J, Baxi SN, Schneider LC, Phipatanakul W. Predicting food challenge outcomes for baked milk: role of specific IgE and skin prick testing. Ann Allergy Asthma Immunol. 2012 Nov;109(5):309-313.e1. doi: 10.1016/j.anai.2012.07.026. Epub 2012 Aug 21.</citation>
    <PMID>23062384</PMID>
  </reference>
  <reference>
    <citation>Rao DR, Gaffin JM, Baxi SN, Sheehan WJ, Hoffman EB, Phipatanakul W. The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma. 2012 Aug;49(6):586-92. doi: 10.3109/02770903.2012.690481. Epub 2012 Jun 28.</citation>
    <PMID>22742446</PMID>
  </reference>
  <reference>
    <citation>Rao D, Phipatanakul W. Impact of environmental controls on childhood asthma. Curr Allergy Asthma Rep. 2011 Oct;11(5):414-20. doi: 10.1007/s11882-011-0206-7. Review.</citation>
    <PMID>21710109</PMID>
  </reference>
  <results_reference>
    <citation>Permaul P, Hoffman E, Fu C, Sheehan W, Baxi S, Gaffin J, Lane J, Bailey A, King E, Chapman M, Gold D, Phipatanakul W. Allergens in urban schools and homes of children with asthma. Pediatr Allergy Immunol. 2012 Sep;23(6):543-9. doi: 10.1111/j.1399-3038.2012.01327.x. Epub 2012 Jun 6.</citation>
    <PMID>22672325</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheehan WJ, Hoffman EB, Fu C, Baxi SN, Bailey A, King EM, Chapman MD, Lane JP, Gaffin JM, Permaul P, Gold DR, Phipatanakul W. Endotoxin exposure in inner-city schools and homes of children with asthma. Ann Allergy Asthma Immunol. 2012 Jun;108(6):418-22. doi: 10.1016/j.anai.2012.04.003. Epub 2012 Apr 26.</citation>
    <PMID>22626594</PMID>
  </results_reference>
  <results_reference>
    <citation>Phipatanakul W, Bailey A, Hoffman EB, Sheehan WJ, Lane JP, Baxi S, Rao D, Permaul P, Gaffin JM, Rogers CA, Muilenberg ML, Gold DR. The school inner-city asthma study: design, methods, and lessons learned. J Asthma. 2011 Dec;48(10):1007-14. doi: 10.3109/02770903.2011.624235. Epub 2011 Oct 20.</citation>
    <PMID>22010992</PMID>
  </results_reference>
  <results_reference>
    <citation>Baxi SN, Sheehan WJ, Gaffin JM, Yodying J, Panupattanapong S, Lane JP, Fu C, Hoffman EB, Gold DR, Phipatanakul W. Agreement between parent and student responses to an asthma and allergy questionnaire in a diverse, inner-city elementary school population. Ann Allergy Asthma Immunol. 2011 Oct;107(4):371-3. doi: 10.1016/j.anai.2011.08.007.</citation>
    <PMID>21962100</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Boston</investigator_affiliation>
    <investigator_full_name>Wanda Phipatanakul</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>childhood</keyword>
  <keyword>allergy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
